About Severe Combined Immunodeficiency
Severe Combined Immunodeficiency encompasses a heterogeneous group of inherited disorders marked by profound defects in both T-cell and B-cell immunity, rendering affected infants susceptible to life-threatening infections by bacteria, viruses, and fungi. Newborn screening programs have enabled earlier identification, dramatically improving outcomes when hematopoietic stem cell transplantation or gene therapy is initiated before infectious complications occur. Without definitive treatment, SCID is uniformly fatal in early childhood.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Severe Combined Immunodeficiency trials.
Gene therapy trials for ADA-SCID and X-linked SCID typically enroll infants without a matched sibling donor; confirm HLA typing results and donor search status before applying
Most interventional trials require patients to be free of active infection at enrollment; timing of application relative to current infectious status is critical
Newborn screening detection status (positive vs. incidental diagnosis) may affect eligibility in natural history studies — report NBS results accurately
Patient Resources
Find recruiting Severe Combined Immunodeficiency trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Severe Combined Immunodeficiency. Updated daily.